Journal of Clinical Virology最新文献

{"title":"The molecular epidemiology of respiratory syncytial virus in Ontario, Canada from 2022-2024 using a custom whole genome sequencing assay and analytics package.","authors":"Henry Wong, Calvin P Sjaarda, Brittany Rand, Drew Roberts, Kyla Tozer, Ramzi Fattouh, Robert Kozak, Prameet M Sheth","doi":"10.1016/j.jcv.2024.105759","DOIUrl":"https://doi.org/10.1016/j.jcv.2024.105759","url":null,"abstract":"<p><strong>Background: </strong>Respiratory Syncytial Virus (RSV) infections are a cause of significant morbidity and mortality in children and the elderly. Despite the clinical burden of disease, very little is known about the inter- and intra-seasonal genomic variability of RSV. Furthermore, the recent approval of vaccines and monoclonal antibody therapies will likely lead to higher selective pressure on RSV. Genomic surveillance will be essential to monitor viral changes and inform future therapeutic developments and public health responses. Here, we describe the development of an amplicon-based whole-genome sequencing assay for RSV to enable genomic surveillance.</p><p><strong>Methods: </strong>A 750-bp overlapping amplicon design was developed to co-amplify RSV-A/-B directly from patient samples collected during two respiratory illness seasons (2022/23, 2023/24) for whole-genome sequencing. RSV subtype, clade, and F-protein antigenic site sequences were determined with a custom analytical pipeline.</p><p><strong>Results: </strong>Of the 429 specimens included in the study 410 (95.6 %) samples met acceptability. Our data demonstrated co-circulation of both RSV subtypes, with increasing predominance of RSV-A since 2022. There were seven genomic clades of RSV-A, while >95 % of RSV-B belonged to a single clade. 1.5 % of samples had amino acid changes within the binding sites of the current RSV therapeutics Palivizumab or Nirsevimab.</p><p><strong>Conclusions: </strong>Continuous monitoring of RSV genotypes and mutations will be critical for understanding the impact of new therapeutics and vaccines on RSV epidemiology and detecting emergence of vaccine-escape and/or antiviral resistant mutations.</p>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"176 ","pages":"105759"},"PeriodicalIF":4.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limited utility of Epstein-Barr virus (EBV) surveillance for predicting post-transplant lymphoproliferative disorders in adult EBV seropositive lung transplant recipients.","authors":"Jordan K Mah, Patrick C K Tam, Yeh-Chung Chang, Jennifer H Saullo, Arthur W Baker, Eileen K Maziarz, Julia A Messina, Beatrice Sim, Lana Abusalem, Sandrine Hanna, Matthew R Pipeling, Laurie D Snyder, John M Reynolds, Cameron R Wolfe, Mark J Lee, Barbara D Alexander, Madeleine R Heldman","doi":"10.1016/j.jcv.2024.105758","DOIUrl":"https://doi.org/10.1016/j.jcv.2024.105758","url":null,"abstract":"<p><strong>Background: </strong>EBV DNAemia surveillance, with reduction of immunosuppression at certain viral load (VL) thresholds, is a common practice for mitigating progression from EBV DNAemia to post-transplant lymphoproliferative disorder (PTLD) in lung transplant recipients (LTRs). The utility of EBV surveillance in adult EBV seropositive LTRs is unknown.</p><p><strong>Methods: </strong>We performed a retrospective cohort study of EBV seropositive adult LTRs who underwent lung transplant between 1/1/19 and 12/31/20 and received whole blood (WB) EBV PCR surveillance. We compared peak WB EBV VLs among 3 groups: 1) asymptomatic LTRs who developed PTLD, before PTLD was clinically suspected, 2) LTRs who developed PTLD, after PTLD was clinically suspected, and 3) LTRs who did not develop PTLD. We calculated the positive predictive value (PPV) of moderate-grade DNAemia (2840 to 11,360 IU/mL) and high-grade DNAemia (≥ 11,360 IU/mL) for identifying active or future PTLD.</p><p><strong>Results: </strong>Six (2.6 %) of 229 LTRs developed PTLD. Among LTRs who developed PTLD, median peak EBV VL was significantly higher after PTLD was suspected than before clinical signs of PTLD were present (16,004 IU/mL vs. ≤568 IU/mL, p = 0.016). Median peak EBV VLs were similar between asymptomatic LTRs who later developed PTLD and LTRs who did not develop PTLD (median peak EBV VL ≤568 IU/mL vs. ≤568 IU/mL, p = 0.62). The PPVs for moderate- and high-grade DNAemia were 14.7 % and 33.3 %, respectively.</p><p><strong>Conclusions: </strong>EBV surveillance did not accurately identify EBV seropositive LTRs at risk for progressing to PTLD. EBV PCR testing in asymptomatic EBV seropositive transplant recipients may represent an opportunity for diagnostic stewardship.</p>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"176 ","pages":"105758"},"PeriodicalIF":4.0,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytomegalovirus urinary excretion in children with congenital and postnatally acquired infection.","authors":"Tatiana M Lanzieri, A Chantal Caviness, Jill J Williams, Gail Demmler-Harrison","doi":"10.1016/j.jcv.2024.105756","DOIUrl":"https://doi.org/10.1016/j.jcv.2024.105756","url":null,"abstract":"<p><strong>Background: </strong>Cytomegalovirus (CMV) infection in children is associated with prolonged viral excretion in urine and saliva. This study characterizes CMV urinary excretion in children with congenital (cCMV) and postnatally acquired CMV infection.</p><p><strong>Methods: </strong>Children with virologically confirmed cCMV (75 symptomatic and 105 asymptomatic at birth) and 51 children without cCMV were followed through median 11, 18 and 17 years of age, respectively. In children with cCMV, duration of CMV excretion was defined as uninterrupted positive results from initial to last positive culture, and recurrent CMV excretion as ≥1 positive following >1 negative result. CMV urinary excretion in children without cCMV was defined as resulting from postnatally acquired CMV infection.</p><p><strong>Results: </strong>Mean duration of persistent CMV urinary excretion in children with cCMV was 1.9 (maximum 8.7) years for symptomatic and 2.8 (maximum 9.8) years for asymptomatic children (P = 0.011). Mean duration of CMV excretion was not statistically different for 17 symptomatic children treated with ganciclovir (2.4 years) compared with 58 untreated (1.8 years); P = 0.356. Recurrent excretion occurred in 19 (25 %) symptomatic and 21 (20 %) asymptomatic children, at mean age 4.0 and 6.2 years, respectively (P = 0.084). In 16 (31 %) children with postnatally acquired CMV infection, CMV urinary excretion began at mean age 1.8 (range 0.3-7.3) years.</p><p><strong>Conclusions: </strong>Both symptomatic and asymptomatic cCMV were associated with persistent long-term CMV excretion in urine, which was significantly longer in asymptomatic cCMV and not influenced by ganciclovir treatment in symptomatic cCMV. CMV urinary excretion was common in young children without cCMV, suggesting rapid CMV acquisition in childhood.</p>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"176 ","pages":"105756"},"PeriodicalIF":4.0,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nucleic acid amplification testing using dried blood spots to confirm the diagnosis of HIV-1 in adults","authors":"Benjamin A. Pinsky ,&nbsp;Malaya K. Sahoo ,&nbsp;Justen Manasa ,&nbsp;Tariro Makadzange ,&nbsp;Carole L. Wallis ,&nbsp;Ed G. Marins ,&nbsp;Nagalingeswaran Kumarasamy ,&nbsp;John A. Bartlett ,&nbsp;Ronald J. Bosch ,&nbsp;Dennis Israelski ,&nbsp;David A. Katzenstein ,&nbsp;A5230 and PARC teams","doi":"10.1016/j.jcv.2024.105746","DOIUrl":"10.1016/j.jcv.2024.105746","url":null,"abstract":"<div><h3>Background</h3><div>The WHO HIV testing algorithm for high prevalence populations recommends the use of three different serologic assays, though this approach may lead to diagnostic misclassification. The study objective was to compare dried blood spot (DBS)-based HIV-1 nucleic acid detection methods to determine their suitability to confirm the diagnosis of HIV-1 in adults generally with suppressed or low-level plasma HIV-1 RNA.</div></div><div><h3>Methods</h3><div>Four methods were evaluated: Cepheid Xpert HIV-1 Qual Assay (Xpert), Hologic Aptima HIV-1 Quant Dx assay (Aptima), Roche Cobas Ampliprep/Cobas TaqMan HIV-1 test, v.2.0 (CAP/CTM) with guanidinium-based sample pre-extraction buffer (SPEX), or CAP/CTM with phosphate-buffered saline (PBS). Testing was performed on 163 DBS samples collected from participants with HIV-1 in the AIDS Clinical Trial Group (ACTG) A5230 study (73 samples) and the Peninsula AIDS Research Cohort (PARC) study (90 samples).</div></div><div><h3>Results</h3><div>Xpert and SPEX CAP/CTM [96.9 % (158/163):95.7 % (156/163); <em>P</em> = 0.75) showed similar sensitivity. However, PBS CAP/CTM and Aptima demonstrated significantly lower sensitivity, 68.2 % (107/157) and 69.2 % (99/143), respectively, compared to Xpert and SPEX CAP/CTM (<em>P</em> &lt; 0.0001 for all comparisons). Overall agreement between Xpert and SPEX CAP/CTM was 93.9 % (153/163), including 152 DBS samples in which both methods detected HIV-1 nucleic acids.</div></div><div><h3>Conclusions</h3><div>Xpert and SPEX CAP/CTM provide sensitive performance for the detection of HIV-1 nucleic acids using DBS collected from adults living with HIV-1, including those with suppressed virus loads. Given the cost and side-effects associated with inappropriate life-long antiretroviral therapy, these assays may play a role in diagnosing HIV-1 infection in individuals with suspected false-positive serologic testing.</div></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"175 ","pages":"Article 105746"},"PeriodicalIF":4.0,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantification of human immunodeficiency virus type 2 (HIV-2) viral load in plasma: Comparison of three commercial assays","authors":"Iker Falces-Romero ,&nbsp;Isabel García-Pérez ,&nbsp;Luz Martín-Carbonero ,&nbsp;Julio García-Rodríguez ,&nbsp;Jesús Mingorance","doi":"10.1016/j.jcv.2024.105745","DOIUrl":"10.1016/j.jcv.2024.105745","url":null,"abstract":"<div><h3>Introduction</h3><div>There are few validated commercially available HIV-2 assays for the measurement of viral load. Our aim was to compare three commercial assays for the quantification of HIV-2 viral load in plasma of patients with HIV-2 infection from our hospital.</div></div><div><h3>Material and methods</h3><div>We conducted a retrospective study at our tertiary-care hospital, analyzing samples from patients with known HIV-2 infection collected between 2022 and 2023. We compared three commercial assays for quantification of the viral load, Biomérieux® NASBA assay, Thermo Fisher® digital PCR (dPCR) assay and Altona® RT-PCR assay.</div></div><div><h3>Results</h3><div>A total of 27 samples from 11 different patients were included in the study. Sixteen out of them were negative across all three assays. One sample had a low viral load (&lt;2 log copies/mL) detected by the three assays. In five samples a low viral load was only detected by the Altona® assay. The remaining five samples, all from the same patient infected by a multidrug-resistant HIV-2, showed detectable viral load up to 2 log copies/mL by the Thermo Fisher® and Altona® assays, but none of these samples were detected by the Biomérieux® assay.</div></div><div><h3>Conclusions</h3><div>The Altona® RT-PCR assay and the ThermoFisher® dPCR assay could be reliable options as commercial assays for the quantification of HIV-2 RNA in plasma. However, the Biomérieux® NASBA assay, despite detecting both HIV-1 and HIV-2, may have limitations for HIV-2 detection in some cases.</div></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"175 ","pages":"Article 105745"},"PeriodicalIF":4.0,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coinfections and iterative detection of respiratory viruses among 17,689 patients between March 2021 and December 2022 in Southern France","authors":"Cédric Mantelli ,&nbsp;Philippe Colson ,&nbsp;Lucile Lesage ,&nbsp;Didier Stoupan ,&nbsp;Hervé Chaudet ,&nbsp;Aurélie Morand ,&nbsp;Bernard La Scola ,&nbsp;Céline Boschi","doi":"10.1016/j.jcv.2024.105744","DOIUrl":"10.1016/j.jcv.2024.105744","url":null,"abstract":"<div><h3>Objectives</h3><div>We aimed to describe coinfections and iterative infections with respiratory viruses diagnosed over a 22-month period in 2021–2022 in public university hospitals of the second largest French city.</div></div><div><h3>Material and methods</h3><div>Respiratory virus infections were diagnosed by qPCR with the Fast Track Diagnostics Respiratory Pathogens 21 on nasopharyngeal swabs collected between 01/03/2021–31/10/2022 and sent for routine diagnosis purpose to our clinical microbiology-virology laboratory at public university hospitals of Marseille, Southern France.</div></div><div><h3>Results</h3><div>Nasopharyngeal swabs from 17,689 patients were tested, of which 8,133 (46 %) were positive for ≥1 respiratory virus and 1,255 (15%) were co-infected with ≥2 viruses including 213 (2.6 %) with 3–7 viruses. Among them, 1,005 (80 %) were younger than 5 years, and mean age was significantly lower for coinfected than monoinfected patients (6.6 versus 23.8 years; <em>p</em> &lt; 0.0001). Viruses with the highest confection rates were HBoV (97 %), HPeV (97 %), EV (92 %), ADV (68 %), and HCoV-HKU1 (63 %). Iterative infections were observed in 96 patients and they involved 10 different viruses.</div></div><div><h3>Conclusions</h3><div>Our study points out that coinfections with respiratory viruses vary over time in prevalence, involve majoritarily young children, and may involve concurrent acute infections or acute-on-chronic infections, which deserves further specific studies.</div></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"175 ","pages":"Article 105744"},"PeriodicalIF":4.0,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance evaluation of the Abbott Alinity Hepatitis C antigen next assay in a US urban emergency department population","authors":"John Prostko ,&nbsp;Richard Rothman ,&nbsp;Yu-Hsiang Hsieh ,&nbsp;Sandra Pearce ,&nbsp;Mark Kilbane ,&nbsp;Karl McAuley ,&nbsp;Edwin Frias ,&nbsp;Russell Taylor ,&nbsp;Hussain Ali ,&nbsp;Carsten Buenning ,&nbsp;Jessica Grieshaber ,&nbsp;Jenna Bedrava ,&nbsp;David Daghfal","doi":"10.1016/j.jcv.2024.105743","DOIUrl":"10.1016/j.jcv.2024.105743","url":null,"abstract":"<div><h3>Introduction</h3><div>HCV antibody assays have been used to screen for HCV, but confirmation of acute infection is dependent on RNA or core antigen testing. The aim of the study was to compare the performance of five HCV test methods, including RNA testing, on a US emergency department population.</div></div><div><h3>Methods</h3><div>Clinical performance metrics were calculated on 708 consenting Johns Hopkins Emergency Department patients who self-reported an increased risk for HCV infection. Detection times of antibody, antigen, and RNA testing were compared using 89 samples from commercially available seroconversion panels. Testing was performed on the Abbott Alinity HCV Ag Next (RUO), Roche Elecsys HCV Duo, Abbott ARCHITECT Anti-HCV, and Elecsys Anti-HCV II assays. RNA testing was performed on the Abbott m2000 system.</div></div><div><h3>Results</h3><div>Overall, 21 (3.0%) participants tested positive for HCV on at least one test, 11 (52.4%) had chronic, 1 (4.8%) had an acute, and 3 (14.3%) had resolved infections. The Alinity HCV Ag Next assay demonstrated 99.43% specificity when compared to RNA testing. The Alinity HCV Ag Next assay also detected 91.67% of the active infections compared to RNA testing, while the Elecsys HCV Duo Ag assay detected only 58.33%. The seroconversion panel testing demonstrated that the Alinity HCV Ag Next assay detects an infection within 0.8 days of an RNA result.</div></div><div><h3>Conclusion</h3><div>The Alinity HCV Ag Next assay demonstrated excellent concordance to RNA testing in a US urban E.D. population. This data supports the utility of Alinity HCV Ag Next in diagnosis of active HCV infections.</div></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"175 ","pages":"Article 105743"},"PeriodicalIF":4.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standardization and evaluation of an in-house ELISA for the detection of rabies antibody in a tertiary care centre in South India","authors":"Kalpana Thangavelu,&nbsp;Hubert D-J Daniel,&nbsp;Rajesh Kannangai,&nbsp;Asha Mary Abraham,&nbsp;Selva Kumar Velladurai,&nbsp;Dr. Shoba Mammen","doi":"10.1016/j.jcv.2024.105742","DOIUrl":"10.1016/j.jcv.2024.105742","url":null,"abstract":"<div><h3>Background</h3><div>Rapid fluorescent focus inhibition test (RFFIT), a neutralization-based assay for <strong>detecting rabies antibodies</strong>, is the gold standard. <strong>The National Action Plan for Dog Mediated Rabies Elimination (NAPRE) is a national program that strategizes the establishment of enzyme-linked immunosorbent assays (ELISA) to detect rabies antibodies.</strong></div></div><div><h3>Objective</h3><div>We developed an in-house ELISA to screen for <strong>rabies antibodies</strong> using rabies vaccine antigen to study vaccine response among health care workers (HCWs) who received pre-exposure prophylaxis and a few animal bite victims who received post-exposure prophylaxis with rabies vaccine.</div></div><div><h3>Study design</h3><div>A prospective study was carried out from April to September 2023 <strong>at</strong> the Department of Clinical Virology of a tertiary care <strong>center</strong> in South India. A total of 161 serum specimens, which included 155 serum samples from study participants and 6 samples from a reference laboratory (as controls), <strong>were</strong> obtained during the study period. Rabies antibody was determined by the in-house standardized ELISA developed using <strong>the rabies vaccine</strong> and compared with the reference assay, RFFIT. The accuracy indices of the in-house ELISA were estimated by MedCalc software (version 22.023).</div></div><div><h3>Results</h3><div>A panel of 86 positive and 75 negative serum samples was used for evaluating the in-house standardized ELISA. <strong>The sensitivity, specificity, positive and negative predictive values of the in-house ELISA were 98.8 %, 100 %, 100 %, and 98.7 % respectively. The accuracy of the in-house ELISA is 99.4 %.</strong></div></div><div><h3>Conclusion</h3><div>ELISA can be a practically feasible and less expensive assay compared to RFFIT which is a cumbersome procedure with a long turn-around time of 3–4 days.</div></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"175 ","pages":"Article 105742"},"PeriodicalIF":4.0,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of yellow fever virus genome in urine following natural infection or vaccination: review of current knowledge 1985–2023.","authors":"Zsofia Igloi ,&nbsp;Laura Pezzi ,&nbsp;Remi N. Charrel ,&nbsp;Marion Koopmans","doi":"10.1016/j.jcv.2024.105740","DOIUrl":"10.1016/j.jcv.2024.105740","url":null,"abstract":"<div><h3>Background</h3><div>Yellow fever virus (YFV) is endemic in the (sub)tropical regions of Africa and South America and is prone to cause epidemics. Molecular testing of YFV by reverse transcription-polymerase chain reaction (RT-PCR) was recently adopted by WHO using blood. Urine is a non-invasive diagnostic specimen which has been proven to be useful in diagnosing several flavivirus infections. Until now, systematic data on the usefulness of urine in YFV molecular diagnostics was lacking.</div></div><div><h3>Methods</h3><div>We have carried out an extensive literature search using key words “yellow fever AND urine” in PubMed/Medline, Embase and Web of Science.</div></div><div><h3>Results</h3><div>The search resulted initially in 113 publications. All titles and abstracts were screened and 15 were analyzed in detail. After natural infection (10 articles), the detection ratio of YFV in blood with RT-PCR was 61 % (105/171 samples) vs. 59 % (139/234) in urine from patients with mild/severe infections. YFV could be first detected at average 4.3 days in blood vs. 6.1 days in urine and last detected till 17.2 vs. 31.1 days respectively (significant difference <em>p</em> &lt; 0.05). Viral load over time in blood was not statistically different from urine. Virus could be isolated from blood, urine and semen. Following vaccination, virus was detected longer in patients with vaccine adverse events (VAE) compared to healthy vaccinees (average 34 vs. 25 days, not significant <em>p</em> &gt; 0.05).</div></div><div><h3>Conclusion</h3><div>YFV can be detected in urine later but longer. Thus, we see added value for YF molecular diagnostics and sequencing and recommend it besides blood as a standard specimen, especially for late samples post onset.</div></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"175 ","pages":"Article 105740"},"PeriodicalIF":4.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical accuracy of OncoPredict HPV Quantitative Typing (QT) assay on self-samples","authors":"Ardashel Latsuzbaia ,&nbsp;Marianna Martinelli ,&nbsp;Chiara Giubbi ,&nbsp;Kate Cuschieri ,&nbsp;Hana Elasifer ,&nbsp;Anna D. Iacobone ,&nbsp;Fabio Bottari ,&nbsp;Andrea F. Piana ,&nbsp;Roberto Pietri ,&nbsp;Giancarlo Tisi ,&nbsp;Franco Odicino ,&nbsp;Clementina E. Cocuzza ,&nbsp;Marc Arbyn ,&nbsp;European VALHUDES working group","doi":"10.1016/j.jcv.2024.105737","DOIUrl":"10.1016/j.jcv.2024.105737","url":null,"abstract":"<div><h3>Background</h3><div>The VALHUDES initiative was established to assess the clinical accuracy of HPV assays to detect cervical precancers using urine and vaginal self-samples compared to cervical clinician-collected samples. Here, the clinical performance of OncoPredict HPV Quantitative Typing (QT) assay (OncoPredict QT) was evaluated.</div></div><div><h3>Methods</h3><div>490 women referred to colposcopy self-collected a urine and a vaginal specimen using Colli-Pee and FLOQSwab, respectively. Subsequently, a colposcopy was performed, and a cervical sample was collected with Cervex-Brush, followed by biopsy if clinically indicated. Vaginal samples were transported dry and resuspended in 5 mL of eNAT medium, whilst cervical brushings were immediately transferred in 20 mL ThinPrep.</div></div><div><h3>Results</h3><div>The clinical sensitivity of OncoPredict HPV QT testing for CIN2+ in urine and vaginal self-samples was similar to cervical samples (ratios of 0.99 [95 % CI 0.94–1.05] and 1.00 [95 % CI 0.96–1.04]), respectively, when manufacturer's cut-offs were applied. The specificity for &lt;CIN2 on both self-samples was lower than on cervical samples (urine/cervical ratio = 0.91 [95 % CI 0.84–0.98]; vaginal/cervical ratio = 0.90 [95 % CI 0.84–0.98]). Cut-off optimisation improved specificity without compromising sensitivity. Median viral load values adjusted for cellularity were significantly higher in cervical samples compared to urine or vaginal self-samples, in general for all 12 high-risk HPV and in particular for HPV16, 18, 31, 33, 35, 45, 51, 58 (<em>p</em> &lt; 0.05). No difference was observed in median viral loads between urine and vaginal samples.</div></div><div><h3>Conclusion</h3><div>Following cut-off optimisation OncoPredict HPV QT assay demonstrated similar accuracy on self-collected versus cervical samples.</div></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"175 ","pages":"Article 105737"},"PeriodicalIF":4.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}